Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
General Thoracic and Cardiovascular Surgery
Erschienen in:

02.11.2019 | Special Edition

New T1 classification

verfasst von: Peter M. F. Lin, Michael K. Hsin

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

The IASLC staging and Prognostic Factor Committee proposed new changes to the descriptors for the 8th edition of the Tumour Node Metastasis Staging for Lung Cancer. The T1 descriptor changes include (1) T1 tumours are subclassified into T1a (< 1 cm), T1b (> 1 to < 2 cm), T1c (> 2 to < 3 cm). The corresponding changes are introduced to the overall staging: T1aN0M0 = Stage IA1; T1bN0M0 = Stage IA2; T1cN0M0 = Stage IA3. (2) The introduction of the pathological entities Adenocarcinoma-In-Situ (AIS), Minimally Invasive Adenocarcinoma, and Lepidic Predominant Adenocarcinoma. The corresponding changes on the T descriptor are as follows: Adenocarcinoma-in situ is coded as Tis (AIS); Minimally Invasive Adenocarcinoma is coded as T1a(mi). In this review, the basis for these changes will be described, and the implications on clinical practice will be discussed.
Literatur
1.
Rami-Porta R, Goldstraw P. Strength and weakness of the new TNM classification for lung cancer. Eur Respir J. 2010;36(2):237–9.PubMedCrossRef
2.
Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10(7):990–1003.PubMedCrossRef
3.
Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A 3rd, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515–22.PubMedCrossRef
4.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.PubMedCrossRef
5.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.PubMedPubMedCentralCrossRef
6.
Travis WDBE, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC publications; 2015.
7.
Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653–64.PubMedCrossRef
8.
Ito M, Miyata Y, Kushitani K, Yoshiya T, Mimae T, Ibuki Y, et al. Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications. Lung Cancer (Amsterdam, Netherlands). 2014;85(2):270–5.CrossRef
9.
Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, et al. The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11(8):1204–23.PubMedCrossRef
10.
Petrou M, Quint LE, Nan B, Baker LH. Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology. AJR Am J Roentgenol. 2007;188(2):306–12.PubMedCrossRef
11.
Burt BM, Leung AN, Yanagawa M, Chen W, Groth SS, Hoang CD, et al. Diameter of solid tumor component alone should be used to establish T stage in lung adenocarcinoma. Ann Surg Oncol. 2015;22(Suppl 3):S1318–23.PubMedCrossRef
12.
Hwang EJ, Park CM, Ryu Y, Lee SM, Kim YT, Kim YW, et al. Pulmonary adenocarcinomas appearing as part-solid ground-glass nodules: is measuring solid component size a better prognostic indicator? Eur Radiol. 2015;25(2):558–67.PubMedCrossRef
13.
Maeyashiki T, Suzuki K, Hattori A, Matsunaga T, Takamochi K, Oh S. The size of consolidation on thin-section computed tomography is a better predictor of survival than the maximum tumour dimension in resectable lung cancer. Eur J Cardio-thorac Surg. 2013;43(5):915–8.CrossRef
14.
Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Solid tumor size on high-resolution computed tomography and maximum standardized uptake on positron emission tomography for new clinical T descriptors with T1 lung adenocarcinoma. Ann Oncol. 2013;24(9):2376–81.PubMedCrossRef
15.
Aokage K, Miyoshi T, Ishii G, Kusumoto M, Nomura S, Katsumata S, et al. Clinical and pathological staging validation in the eighth edition of the TNM classification for lung cancer: correlation between solid size on thin-section computed tomography and invasive size in pathological findings in the new T classification. J Thorac Oncol. 2017;12(9):1403–12.PubMedCrossRef
16.
Ahn H, Lee KW, Lee KH, Kim J, Kim K, Chung JH, et al. Effect of computed tomography window settings and reconstruction plane on 8th edition T-stage classification in patients with lung adenocarcinoma manifesting as a subsolid nodule. Eur J Radiol. 2018;98:130–5.PubMedCrossRef
17.
Kakinuma R, Noguchi M, Ashizawa K, Kuriyama K, Maeshima AM, Koizumi N, et al. Natural history of pulmonary subsolid nodules: a prospective multicenter study. J Thorac Oncol. 2016;11(7):1012–28.PubMedCrossRef
18.
Lee SM, Goo JM, Lee KH, Chung DH, Koh J, Park CM. CT findings of minimally invasive adenocarcinoma (MIA) of the lung and comparison of solid portion measurement methods at CT in 52 patients. Eur Radiol. 2015;25(8):2318–25.PubMedCrossRef
19.
Yanagawa M, Johkoh T, Noguchi M, Morii E, Shintani Y, Okumura M, et al. Radiological prediction of tumor invasiveness of lung adenocarcinoma on thin-section CT. Medicine. 2017;96(11):e6331.PubMedPubMedCentralCrossRef
20.
Yanagawa M, Kusumoto M, Johkoh T, Noguchi M, Minami Y, Sakai F, et al. Radiologic-pathologic correlation of solid portions on thin-section CT images in lung adenocarcinoma: a multicenter study. Clin Lung Cancer. 2018;19(3):e303–12.PubMedCrossRef
21.
Detterbeck FC, Chansky K, Groome P, Bolejack V, Crowley J, Shemanski L, et al. The IASLC Lung Cancer Staging Project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (Eighth) edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11(9):1433–46.PubMedCrossRef
22.
Yang L, Wang S, Zhou Y, Lai S, Xiao G, Gazdar A, et al. Evaluation of the 7(th) and 8(th) editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget. 2017;8(40):66784–95.PubMedPubMedCentralCrossRef
23.
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer: Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615–22 (discussion 22-3).PubMedCrossRef
24.
Bao F, Ye P, Yang Y, Wang L, Zhang C, Lv X, et al. Segmentectomy or lobectomy for early stage lung cancer: a meta-analysis. Eur J Cardio-Thorac Surg. 2014;46(1):1–7.CrossRef
25.
Cao C, Chandrakumar D, Gupta S, Yan TD, Tian DH. Could less be more?-A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. Lung Cancer (Amsterdam, Netherlands). 2015;89(2):121–32.CrossRef
26.
El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surgery. 2006;82(2):408–15 (discussion 15-6).CrossRef
27.
Okami J, Ito Y, Higashiyama M, Nakayama T, Tokunaga T, Maeda J, et al. Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. Ann Thorac Surg. 2010;90(5):1651–6.PubMedCrossRef
28.
Cao J, Xu J, He Z, Yuan P, Huang S, Lv W, et al. Prognostic impact of lymphadenectomy on outcomes of sublobar resection for stage IA non-small cell lung cancer ≤2 cm. J. Thorac. Cardiovasc Surg. 2018;156(2):796–805.PubMedCrossRef
29.
Liu Y, Huang C, Liu H, Chen Y, Li S. Sublobectomy versus lobectomy for stage IA (T1a) non-small-cell lung cancer: a meta-analysis study. World J Surg Oncol. 2014;12:138.PubMedPubMedCentralCrossRef
30.
Speicher PJ, Gu L, Gulack BC, Wang X, D’Amico TA, Hartwig MG, et al. Sublobar resection for clinical stage IA non-small-cell lung cancer in the United States. Clin Lung Cancer. 2016;17(1):47–55.PubMedCrossRef
31.
Yendamuri S, Dhillon SS, Groman A, Dy G, Dexter E, Picone A, et al. Effect of the number of lymph nodes examined on the survival of patients with stage I non-small cell lung cancer who undergo sublobar resection. J Thorac Cardiovasc Surg. 2018;156(1):394–402.PubMedCrossRef
32.
Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018;6(12):915–24.PubMedPubMedCentralCrossRef
33.
Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40(3):271–4.PubMedCrossRef
Metadaten
Titel
New T1 classification
verfasst von
Peter M. F. Lin
Michael K. Hsin
Publikationsdatum
02.11.2019
Verlag
Springer Singapore
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 7/2020
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-019-01233-0

Weitere Artikel der Ausgabe 7/2020

Computed tomography screening for lung cancer

  • Special Edition

Preface

  • Special Edition

Are segmentectomy and lobectomy comparable in terms of curative intent for early stage non-small cell lung cancer?

  • Special Edition

The diagnosis and treatment of lung cancer presented as ground-glass nodule

  • Special Edition

Photodynamic therapy for central-type early-stage lung cancer

  • Special Edition

Precise sublobar lung resection for small pulmonary nodules: localization and beyond

  • Special Edition

Neu im Fachgebiet Chirurgie

Krebs-Op. besser erst nach mehrwöchigem Rauchverzicht?

Aktive Raucher haben nach onkologischen Operationen ein höheres Komplikationsrisiko als Nieraucher, aber auch als Exraucher. Damit der Rauchstopp einen Nutzen hat, darf er aber nicht zu kurz vor der Op. erfolgen, wie eine Metaanalyse nahelegt.

Periprozeduraler Myokardschaden nach NSTEMI prognostisch bedeutsam

Erleiden NSTEMI-Patienten und -Patientinnen infolge einer PCI Myokardschädigungen mit oder ohne Infarkt, erhöht das die Gesamtmortalität und das Risiko für weitere schwere Herzereignisse. Dafür sprechen zumindest Daten aus zwei italienischen Zentren.

Höhere Sterberate nach Freitags-Op.

Wer direkt vor dem Wochenende operiert wird, läuft eher Gefahr, in den folgenden Wochen und Monaten zu sterben, als Menschen mit einer Op. unmittelbar nach dem Wochenende. Der Unterschied bei der Sterberate beläuft sich nach Daten einer US-Analyse auf etwa 10%.

Ärztinnen überholen Ärzte bei Praxisgründungen

Bei Praxisgründungen haben inzwischen die Frauen deutlich die Nase vorn: Seit zehn Jahren wagen laut apoBank mehr Ärztinnen als Ärzte den Schritt in die Selbstständigkeit. In puncto Finanzierung sind sie aber vorsichtiger als die männlichen Kollegen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise